Indian multinational biopharmaceutical company
POPULARITY
27 episodes with Biocon
30 episodes with Biocon
30 episodes with Biocon
7 episodes with Biocon
2 episodes with Biocon
9 episodes with Biocon
2 episodes with Biocon
2 episodes with Biocon
2 episodes with Biocon
We decode how India's economy is defying the odds, going strong despite headwinds. And also take a look at a spurt in trading using algorithms facilitated by modern digital platforms. And then unveil Biocon's desire to be a dominant force in the fight against diabetes and obesity. Finally, we share insights on how India's poised to be a global AI leader with OpenAI readying offerings in Hindi and Tamil. Tune in.
It's Thursday, March 6th, 2025. This is Nelson John, let's get started. ITC Hotels' Rough Debut January 29 was supposed to be a landmark day for ITC Hotels as it began trading independently. However, shares debuted nearly 30% below the implied price, dampening initial enthusiasm. Despite this, analysts remain bullish, valuing the company between ₹42,500-₹62,000 crore. ITC Hotels aims to expand to 200 hotels with 18,000 rooms in five years, relying on managed properties. However, investors worry about its limited owned-hotel pipeline. As competitors like IHCL and Marriott ramp up expansion, ITC Hotels must carve out its niche in a booming industry. Coforge's Record-Breaking Deal Coforge Ltd soared 8% after securing a record 13-year, $1.56 billion deal with US travel tech giant Sabre Corp. This long-term contract ensures strong revenue visibility for FY26, even as tech budgets shrink. Coforge also acquired Rythmos Inc. for $48.7 million and TMLabs for $12.5 million, further expanding its portfolio. A 1:5 stock split was announced to boost liquidity. However, Sabre's $5.1 billion debt raises cash collection concerns. Despite this, Coforge has outperformed peers, with its December order book reaching $1.4 billion—up 40% YoY. Tesla, Tariffs & Trump India's sky-high auto tariffs—up to 110%—have kept foreign automakers like Tesla out, despite Elon Musk's repeated attempts to enter the market. Now, US President Donald Trump has joined the fight, slamming India's “unfair” tariffs and threatening retaliatory action. As trade negotiations intensify, India has begun cutting duties on luxury vehicles—a possible opening for Tesla. With Trade Minister Piyush Goyal in the US for talks, the world watches to see if India will open its doors to global carmakers or protect its domestic industry. Cancer Drug Prices Set to Fall Cancer treatment in India is notoriously expensive, with some drugs costing up to ₹2 lakh per month. That's changing, thanks to domestic production under the government's PLI scheme. Leading pharma firms like Sun Pharma, Cipla, and Biocon are now manufacturing key cancer drugs, significantly cutting prices. For example, Trastuzumab, once ₹70,000 per month, now costs ₹12,000. More price reductions are expected as local production scales up. The initiative not only benefits Indian patients but also strengthens India's role as the “pharmacy of the world,” with exports to South America and Africa. Rupee Rises Amid Market Rally The rupee strengthened by 19 paise to close at 87.00 against the US dollar, supported by a rally in domestic equities, a weaker dollar, and falling crude oil prices. Volatility remained high, with the currency fluctuating between 86.93 and 87.20. Meanwhile, the dollar index slipped 0.79% amid Trump's escalating tariff moves. Brent crude also declined 0.75% to $70.51 per barrel. Markets responded positively, with the Sensex surging 740 points to 73,730 and the Nifty rising 255 points to 22,337. However, FII outflows and ongoing trade uncertainties could limit further rupee gains.
In today's episode of Market Minutes, Vaibhavi Ranjan takes you through the key market trends for March 5. Indian equities are set for a flattish open, with GIFT Nifty hinting at a muted start for Sensex and Nifty 50. The benchmark indices extended their losing streak in the previous session, with Nifty recording its 10th straight day of declines—a first in history. Meanwhile, global markets remain on edge as Trump's tariff policies fuel economic uncertainty. On the stock radar, Biocon gains attention after its US FDA approval for two cancer drugs, while Adani Wilmar's acquisition of GD Foods Manufacturing puts it in the spotlight. Tune in for market insights, expert opinions, and all the latest stock action!
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: New drug is looked at for T1D prevention, a new stem cell method is tested for beta cell transplanation without immunosuppresion drugs, the FDA okays the first fast-acting biosimilar insulin, Lilly lowers price of Zepbound, and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX New research in type 1 diabetes prevention launches. Nektar Therapeutics and TrialNet will evaluate a drug currently used for exzema for patients with new onset stage 3 type 1 diabetes The drug is RezPeg – that's a shortened version of the name (rezpegaldesleukin) This will be a study of about 70 adults and children and will launch this year. The new study will use a mixed meal tolerance test (MMTT) to measure the efficacy of rezpegaldesleukin or placebo for preserving C-peptide area under the curve over a 12-month duration comprised of a 6-month treatment period and a 6-month follow-up. Secondary objectives include pharmacokinetics, pharmacodynamics, and additional disease assessments including HbA1c levels and patient insulin requirements. Rezpegaldesleukin is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases. https://www.prnewswire.com/news-releases/nektar-announces-clinical-trial-agreement-to-evaluate-rezpegaldesleukin-in-patients-with-new-onset-type-1-diabetes-mellitus-302383052.html XX NLS Pharmaceutics (NLSP) and Kadimastem announced successful completion of a pre-IND meeting with the FDA for iTOL-102, a potential diabetes treatment. iTOL-102 combines Kadimastem's IsletRx cells (stem cell-derived pancreatic islets) with iTolerance's immunomodulator iTOL-100, aiming to cure Type 1 Diabetes without requiring life-long immune suppression. The treatment was evaluated at the Diabetes Research Institute at the University of Miami School of Medicine, where it demonstrated functional insulin release and disease reversal in animal models. Based on FDA feedback, the companies are updating plans for safety toxicology studies and First-in-Human clinical trials. IsletRx is a clinical-grade product comprising human pancreatic islet-like cells capable of secreting insulin, offering a scalable source of insulin-producing cells to address donor islet shortages. The technology can detect glucose levels and produce required amounts of insulin and glucagon. XX FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has given a thumbs up to Sanofi's Merilog (insulin-aspart-szjj) as the first biosimilar to Novo Nordisk's NovoLog for patients with diabetes. Merilog will be provided by prefilled pen in a 3 mL dose or in a multiple-dose 10 mL vial. It is for adults and pediatric patients age 6 and older. NovoLog and Novo Nordisk's other rapid-acting insulin follow-on Fiasp are among the drugs subject to government price negotiations under the Inflation Reduction Act. The new prices will be enacted at the start of next year. In July 2021, the FDA approved Biocon and Viatris' Semglee (insulin glargine-yfgn) as the first biosimilar to Lantus. Five months later, the U.S. regulator endorsed Eli Lilly's version of the drug, called Rezvoglar (insulin glargine-aglr). https://www.fiercepharma.com/pharma/fda-signs-sanofis-biosimilar-first-novo-nordisks-rapid-acting-novolog XX Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. The company launched 7.5 mg and 10 mg vials of tirzepatide, sold under the brand name Zepbound, which typically cost $599 and $699, respectively. However, they are now available for $499 per month for patients paying without insurance. This applies to the first fill and all refills that are delivered every 45 days. Additionally, the company lowered the prices of the 2.5 mg and 5 mg vials to $349 and $499 per month, respectively. The company, which has seen a significant boost in profits from Zepbound and Mounjaro – essentially the same drug with different FDA-approved uses – announced that the new vials and pricing are exclusively available through the company's self-pay pharmacy, LillyDirect Self Pay Pharmacy Solutions. https://www.bloomberg.com/news/articles/2025-02-25/zepbound-cost-for-vials-cut-to-battle-cheaper-copycats XX Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a five-year period and could reach $102 billion next year, an analysis by Health and Human Services' inspector general found. The findings also come as the Trump administration weighs the fate of a Biden administration proposal that would require Medicare and Medicaid to cover GLP-1s for weight loss. The biggest spikes in usage were for Rybelsus, Novo Nordisk's once-daily GLP-1 tablet, and for the company's weekly injectable Ozempic, whose spending about doubled every year under review. https://www.axios.com/2025/02/25/medicare-spending-surge-diabetes-drugs XX Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up Control IQ for use in adults with Type 2 diabetes. The expanded label was based on data from a pivotal, randomized trial of more than 300 people with Type 2 diabetes, comparing its use to manual multiple daily injections. Tandem said it plans to present the study's results at the annual Advanced Technologies & Treatments for Diabetes meeting scheduled for next month in Amsterdam. https://www.fiercebiotech.com/medtech/tandem-diabetes-care-insulin-dosing-algorithm-nets-fda-clearance-type-2-diabetes XX Drugs approved for diabetes and obesity might be useful for the treatment of cognitive and mental health disorders, according to a new paper published in Nature Mental Health. The study reviewed and integrated data from both preclinical and clinical studies to gather evidence on the possible effects of these drugs GLP1s and semaglutide in conditions such as dementia, substance use disorders, psychotic disorders, mood and anxiety disorders, and eating disorders. The study found promising but still preliminary evidence that GLP-1RAs could be beneficial over a range of cognitive and mental health disorders. These drugs have shown potential in improving cognition, reducing addictive behavior, and alleviating depression and anxiety. More data from robustly designed studies (i.e., randomized controlled trials) are needed to better understand GLP-1RAs' prospective efficacy and safety profile, especially with long-term use. https://medicalxpress.com/news/2025-02-diabetes-drugs-mental-health-treatment.html XX The FDA issued draft guidance that includes recommendations to support the development and marketing of safe and effective AI-enabled The guidance, if finalized, would be the first guidance to provide comprehensive recommendations for AI-enabled devices throughout the total product lifecycle, providing developers with an accessible set of considerations that tie together design, development, maintenance, and documentation recommendations to help ensure the safety and effectiveness of AI-enabled devices. FDA is requesting public comment on this draft guidance by April 7. The agency also released draft guidance for the use of AI to support regulatory decision-making for drug and biological products. https://www.mddionline.com/artificial-intelligence/fda-issues-draft-guidance-for-ai-enabled-devices-seeks-public-feedback XX Congrats to Mila Clarke who some of you may know better as Hangry Woman on social. She has developed a great app called Glucose Guide and the Nutrition Assistant portion of that app went live this week. Glucose Guide is a web and mobile app that offers diabetes meal tracking, coaching, resources, recipes and community to those looking for help managing diabetes. MEAL AND BLOOD SUGAR TRACKING FEATURES.
Join us as we talk to Sachin Agarwal, the Co-founder of Bizongo about their story. This is yet another episode with a Bizongo co-founder! Last time, in March 2022, we had Ankit Deb. Today, we have Sachin, who completed his B.Tech in Chemical Engineering from IIT Bombay in 2012. He went on to work with leading companies like PepsiCo and Biocon before serving as a Risk Manager at Gravitas. In 2014, he co-founded Bizongo.
Welcome to CNBC-TV18's Marketbuzz Podcast. Here is are top news from around the world ahead of the trading session of January 13 -This week, all eyes will be on corporate earnings, with HCL Tech, Reliance Industries, Infosys, Axis Bank, and Wipro scheduled to release their results. -Key macroeconomic indicators, including CPI and WPI inflation data, will be closely monitored. Market sentiment will also depend on ongoing foreign fund flows and cues from US markets. -US stocks sold off on Friday, with the S&P 500 erasing its 2025 gains, after an upbeat jobs report stoked fresh inflation fears, reinforcing bets that the Federal Reserve will be cautious in cutting interest rates this year. Wall Street's main indexes closed their second consecutive week in the red. -Stocks slipped in Asia following Friday's strong US jobs data, while oil rose to the highest in more than four months as a fresh wave of US sanctions against Russia threatened to crimp supplies. Shares in Australia and South Korea both fell from the open, pressuring a gauge of the region's shares that's now declined for four consecutive sessions. US equity futures also edged lower after the S&P 500 slipped 1.5% Friday. Japanese markets are closed Monday, which means there's no trading in cash Treasuries in Asian hours. -Global crude benchmark Brent advanced above $81 a barrel, after surging almost 4% in the previous session. The US imposed its most aggressive and ambitious sanctions yet on Russia's oil industry on Friday, targeting two large exporters, insurance companies, and more than 150 tankers. -The GIFT Nifty was trading lower at a discount of more than 150 pts from Nifty Futures Friday close, indicating a gap-down start for the Indian market. -Stocks to watch: HCL Tech, Avenue Supermarts, Just Dial, Adani Wilmar, Waaree Energies, Indian Overseas Bank, Biocon, Sunteck Realty Tune in to the Marketbuzz Podcast for more cues
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Takeda, Roche, and Gilead have recently made significant deals in the pharmaceutical industry. Takeda's investment of up to $1.3 billion in Keros' blood cancer anemia drug is making waves, potentially challenging Bristol Myers Squibb. Roche has joined forces with Cour in a deal focused on autoimmune diseases, valued at over $900 million. Meanwhile, Gilead is reentering the ADC space with a potential $415 million license agreement.In other news, Intra-Cellular is seeking approval for Caplyta in major depressive disorder, a move that could result in $1 billion in sales. Unfortunately, Alligator has been forced to reduce its staff by 70% due to capital constraints. On a brighter note, Biocon has received FDA approval for a biosimilar to J&J's Stelara, and Applied Therapeutics is making strides in the fight against deadly brain cancer.However, Bluebird's gene therapy Skysona is currently under FDA safety probe for hematologic malignancies, raising concerns within the industry. Despite this setback, the pharmaceutical industry as a whole continues to see growth and innovation on multiple fronts.
Marketbuzz Podcast: Indian markets may open in the red according to the GIFT Nifty. Watch out for stocks like L&T, Dabur, IRB Infra, Tata Power and Biocon.
Marketbuzz Podcast: Indian markets may see a slightly negative start according to the GIFT Nifty. Watch out for stocks like BSE, Pharma names like Biocon and Welspun Corp.
Welcome to CNBC-TV18's Marketbuzz Podcast. Here are top developments from around the world ahead of today's trading session -Thursday resulted in a sixth straight day of gains for the Nifty and this six-day winning streak itself has resulted in gains of over 800 points for the index, powered by the index heavyweights HDFC Bank and ICICI Bank. The Nifty Bank has been a key catalyst in this surge that the Nifty has seen going into a fresh series. -Auto stocks led by Maruti powered the Nifty ahead during Thursday's trading session. India's largest passenger car manufacturer now has a market capitalisation of well over ₹4 lakh crore. The other bits of gains came from Metal stocks, which continued to rally on hopes of further stimulus being injected in China. -Friday's trading session will see the Nifty index rejig taking place post closing and Trent and Bharat Electronics (BEL) will become part of the Nifty 50, replacing LTIMindtree and Divis Laboratories. There will also be rejig in the Nifty Bank and the Nifty 500, and an increase and decline in weightage in a lot of stocks. - GIFT Nifty was trading with a premium of 45 points from Nifty Futures' Thursday close, indicating a start in the Green for the Indian market. Stocks in focus: IT stocks, Prataap Snacks, Biocon, Nuvama Wealth Management, KEC International, Thangamayil Jewellers, Adani Green Energy, RailTel, RITES, Indian Bank, NTPC Green -Stocks in Asia extended gains as risk appetite across financial markets got a further boost from China's latest stimulus measures and upbeat US momentum. Equities in Australia advanced, while China's benchmark CSI 300 Index is set for its biggest weekly gain in almost a decade after officials pledged to increase fiscal support and stabilize the property sector to revive growth. -Overnight, in the US, revised data showed the US economy in better shape than initially expected, spurred mainly by bigger consumer-driven growth fueled by robust incomes. A decline in US jobless claims underscored the resilience of the labor market. But investors tuning into commentary from Fed Chair Jerome Powell on Thursday didn't get any details on the economic outlook or path for monetary policy. -Thursday's Wall Street trading session ended on a strong note, with the three major averages posting gains and the S&P 500 closing at a fresh record for the third time this week. The Nasdaq Composite also notched four straight winning days. -In commodities, oil slid further as Saudi Arabia was reportedly committed to increasing output in December, while Libya named its new central bank governor, opening the way to reviving some crude production. Copper rallied back above $10,000 a ton and iron ore broke through $100 while gold hit yet another record high on Thursday. Tune in to the Marketbuzz Podcast for more cues
Kiran Mazumdar-Shaw built a pharmaceutical empire after failing to get a job brewing beer. She also overcame gender bias to become India's first self-made female billionaire. Her company Biocon is now Asia's biggest insulin producer. BBC business editor Simon Jack and journalist Zing Tsjeng follow her story, from a childhood living on a brewery compound in Bangalore to adventures in Australia and Ireland. How did Kiran Mazumdar-Shaw go from extracting enzymes from papaya fruit to mass-manufacturing medicines and being named among Time magazine's most influential people in the world? She calls herself an accidental entrepreneur; Simon and Zing decide whether they think she's good, bad or just another billionaire.
In this episode of Market Minutes, Nandita Khemka talks about the key factors to watch out for today. The Indian equity market erased some of Wednesday's gains amid high volatility post the RBI's hawkish pause in the August bi-monthly monetary policy. The Nifty settled the weekly expiry day on a weak footing at 24,117 with a loss of 180 points. Will Nifty manage to chart a clear direction after breaking below 24,200? Among stocks to watch, Eicher Motors, LIC, Biocon will be in focus. Meanwhile, electric 2-wheeler maker Ola Electric is slated to make its debut on the bourses today. Also catch Jyoti Prakash Gadia, Managing Director at Resurgent India in the Voice of the Day segment. Market Minutes is a morning podcast that puts the spotlight on hot stocks, key data points, and developing trends.
Welcome to CNBC-TV18's Marketbuzz Podcast. Here are all the important cues ahead of the trading session of Juen 4 -India's marathon election enters its final phase today with the counting of more than 640 million votes in the world's largest democratic exercise. Most exit polls widely expect the return of Prime Minister Narendra Modi to a third term after a decade in power. -Bulls seem set for a super Tuesday. GIFT Nifty indicates a gap-up start for the Indian market. It's expected to build on to Monday's record gains -The Nifty witnessed the biggest single-day gain in absolute terms on record on June 3, after the exit polls predicted a thumping majority for the Narendra Modi-led NDA government for the third straight term. -The Nifty's 733-point advance, surpassed the 708-point surge it had witnessed in April 2020. BSE-listed companies together added ₹14 lakh crore in market capitalisation. -Almost every sector barring IT participated in the rally yesterday. Reliance Industries hit a record high with its market capitalisation returning above the ₹20 lakh crore mark. Both SBI and ICICI Bank also hit record highs and crossed ₹8 lakh crore in market cap in the process. SBI is now the third most valued bank in the country in market cap terms after HDFC Bank and ICICI Bank. -All eyes are now on the counting. Brokerage firm Nomura wrote in its note that in both 2014 and 2019, the exit polls had underestimated the NDA-seat count by 50 seats and if trend continues on Tuesday, the final NDA tally may turn out to be even better than what has been projected. -Globally, Asia stocks dipped this morning after kicking off June on solid ground, with investors now awaiting the final results of India's general elections. -Overnight, U.S. stock index futures were listless as Wall Street looked to find its footing after an uneven start to the month. Futures for the Dow Jones Industrial Average were roughly flat. S&P 500 futures and Nasdaq 100 futures ticked up less than 0.1% each. The Dow fell more than 115 points, or 0.3%, on the first trading day of June. The S&P 500 and Nasdaq Composite both rose modestly on Monday. -Stocks to track: Zee Entertainment, Kalyan Jewellers, Sapphire Foods, Biocon, Mahindra & Mahindra Financial Services, RVNL, Veranda Learnings, Sanofi India, Capacite Infra Stay tuned to CNBC-TV18 for election results, market action, political views, investor and industry opinion, and more
Welcome to CNBC-TV18's Marketbuzz Podcast. Here are all the important cues ahead of the trading session of May 21 -It's a truncated week as the markets were closed on Monday due to voting in Mumbai in the fifth phase of Lok sabha elections 2024. -In the special trading session on Saturday, the Nifty clawed back above the mark of 22,500, which is one of the two levels the charts were pointing towards once the index sustained above 22,300. All of the losses from the week earlier were recovered as it went up 2% in the extended week gone by, bringing the Nifty back to where it was at the start of the month. -The Nifty Bank has now sustained above the level of 48,000 for two days in a row and chartists have been wanting the index to sustain above that level for a potential move towards 48,500 on the upside. The index has gained in five out of the last six trading sessions and managed to recover half of the 3.1% fall it had in the week prior to last. -The other positive aspect for the domestic market is that foreign institutions turned net buyers in the cash market during Friday's trading session. This happened for the first time in the month of May. -Results today: BHEL, NMDC, PI Industries, IRCON, JK Tyre, GSFC, Metropolis, Laxmi Organic, VA Tech Wabag, Gulf Oil -Stocks to watch out for are SAIL, Ujjivan Small Finance Bank, Anupam Rasayan, India Cements, Whirlpool of India, City Union Bank, Lupin, Biocon, Oil India, Patanjali Foods -Overnight in the US, the Dow Jones Industrial Average lagged the broader market, in contrast to the Nasdaq, as JPMorgan Chase led losses. -All eyes will now be on Nvidia that reports earnings on wednesday. Nvidia shares gained more than 2% overnight on multiple bullish analyst calls that highlighted the company's preeminent market position. -Asia-Pacific markets started mixed this morning. Investors in Asia will be watching for any spillover effect on companies up and down Nvidia's value chain, such as Taiwan's TSMC and Foxconn, as well as South Korea's Samsung Electronics and SK Hynix. -Oil prices fell in early Asian trade this morning, with investors anticipating higher-for-longer U.S. inflation and interest rates will depress consumer and industrial demand. Brent crude futures declined to $83.34 a barrel. -GIFT Nifty traded with a premium of more than 60 points this morning from Nifty Futures' Friday close, indicating a start in the green for the Indian market Tune in to the Marketbuzz Podcast for more cues
Marketbuzz Podcast: Indian markets may see a slightly positive start according to the GIFT Nifty. Watch out for stocks like Vodafone Idea, Vedanta and Bandhan Bank.
Episode Description: Erum and Karl welcome renowned environmentalist, Murali Muthuswamy. He is the founder and chairman of Jananom Private Limited, founder of Elive Biotherapeutics USA, and advisor to Natural Nutrition. Murali explains the urgent and complex challenges of sustainable development. He also talks about the intricate balance required to meet the needs of the present without compromising the future. Exploring innovative solutions, Murali shines a light on groundbreaking technologies and community-driven initiatives that are paving the way for a more sustainable world. This episode not highlights the critical issues but also inspires action, making it a must-listen for anyone interested in shaping a sustainable future. Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing? Learn more at www.messaginglab.com/groweverything Chapters: 00:00:00 - Opening Welcome to Grow Everything: Diving into Today's Special Guest Intro with Shelby Newsad 00:01:29 - Global Explorations: Uncovering Insights from Australia and Brazil 00:04:15 - Climate Biotech Symposium: A Nexus of Networking and Innovation 00:11:32 - Sustainable Innovations: Case Studies of Success 00:13:12 - Trailblazing Paths: Murali Muthuswamy's Entrepreneurial Saga 00:17:04 - From Vision to Reality: Scaling Sustainable Solutions 00:20:21 - The Role of Policy in Supporting Eco-Innovations 00:24:42 - At the Cutting Edge: Synthetic Biology's Battle Against Cancer 00:26:50 - Green Tech: Harnessing Renewable Energy Sources 00:30:33 - Eco-Friendly Manufacturing: Reducing Carbon Footprints 00:34:10 - The Economic Impact of Sustainable Practices 00:38:39 - Innovative Approaches to Oncology: Smart Microorganisms at Work 00:40:17 - Redefining Pharmaceuticals: The Synthesis of Biology and Drug Development 00:41:52 - Exploring the Promise of Living Biotherapeutics 00:45:03 - Digital Meets Biological: Transforming Research and Applications 00:50:12 - India's Ambitious Stride into Biomanufacturing 00:52:20 - Fostering Future Leaders in Biotech Entrepreneurship 00:55:50 - In the Limelight: Breakthroughs from Leading Biotech Firms 00:58:44 - Converging Worlds: Digital Integration in Modern Biotechnology 01:01:15 - Conclusion: Celebrating the Advances in Biotech Innovation Episode Links: Compound VC (link) Genspace (link) Evolva (link) India Institute of Chemical Technology (link) Department of Biotechnology in India (link) Biocon (link) Tata Elxsi (link) Avisa Myko (link) Synonym Biomanufacturing (link) Scaling Cells, Dreaming Big: The Biomanufacturing Cloud with Synonym's Edward Shenderovich (link) Homeworld Collective (link) Cascade Biocatalysts (link) SentiBio (link) Encellin (link) Get $300 off Synbiobeta tickets (May 6-9 in San Jose, CA) using promo code: Grow Everything Topics Covered: synthetic biology, synbio, bioengineering, organism engineering, microbiology Have a question or comment? Message us here: Text or Call (804) 505-5553 Instagram / TikTok / Twitter / LinkedIn / Youtube / GrowEverything website Email: groweverything@messaginglab.com Support here: Patreon Music by: Nihilore Production by: Amplafy Media --- Send in a voice message: https://podcasters.spotify.com/pod/show/messaginglab/message
This “In Conversation with the Mystic” will see Sadhguru in a lively and insightful discussion with Kiran Mazumdar-Shaw, a pioneer of the biotechnology industry in India and the founder of the country's leading biotechnology enterprise, Biocon. Conscious Planet: https://www.consciousplanet.org Sadhguru App (Download): https://onelink.to/sadhguru__app Official Sadhguru Website: https://isha.sadhguru.org Sadhguru Exclusive: https://isha.sadhguru.org/in/en/sadhguru-exclusive Inner Engineering Link: isha.co/ieo-podcast Yogi, mystic and visionary, Sadhguru is a spiritual master with a difference. An arresting blend of profundity and pragmatism, his life and work serves as a reminder that yoga is a contemporary science, vitally relevant to our times. Learn more about your ad choices. Visit megaphone.fm/adchoices
This “In Conversation with the Mystic” will see Sadhguru in a lively and insightful discussion with Kiran Mazumdar-Shaw, a pioneer of the biotechnology industry in India and the founder of the country's leading biotechnology enterprise, Biocon. Conscious Planet: https://www.consciousplanet.org Sadhguru App (Download): https://onelink.to/sadhguru__app Official Sadhguru Website: https://isha.sadhguru.org Sadhguru Exclusive: https://isha.sadhguru.org/in/en/sadhguru-exclusive Inner Engineering Link: isha.co/ieo-podcast Yogi, mystic and visionary, Sadhguru is a spiritual master with a difference. An arresting blend of profundity and pragmatism, his life and work serves as a reminder that yoga is a contemporary science, vitally relevant to our times. Learn more about your ad choices. Visit megaphone.fm/adchoices
Welcome to Top of the Morning by Mint, your weekday newscast that brings you five major stories from the world of business. It's Tuesday, April 9, 2024. My name is Nelson John. Let's get started:Indian equity markets surged on Monday. Nifty and Sensex increased by around 0.6 percent each, hitting fresh record highs. The Bombay Stock Exchange's total market cap crossed the 400 trillion rupee mark for the first time during yesterday's trading session, as global crude oil prices dropped further.Chennai-based Veritas Finance, a private lender to small businesses, , is heading for the public markets soon. Mint's new economy reporters Ranjani Raghavan and Sneha Shah report that Veritas is looking to raise 2,000 crore rupees. It has appointed four entities: Kotak Mahindra, HDFC Securities, ICICI Securities, and Jeffries, to help with the share issue. Last year, the company raised 1,200 crore rupees from a clutch of private equity investors. Veritas specialises in offering loans to small and medium enterprises in semi-urban and rural areas, with an average ticket size of 5 lakh rupees.These days, banks are offering relatively high interest rates even for a simple savings account. It's a simple supply-and-demand equation: they want more money as deposits, so they can offer more loans to applicants. According to the latest data released by the Reserve Bank of India, 80% of deposits in banks are now being doled out as loans. This number is called the credit-deposit ratio, and is at its highest mark since the RBI started recording this data in 2005. Mint's banking correspondent Shayan Ghosh analyses this data, which is buoyed by the merger between the blockbuster HDFC merger. Some analysts expect the credit-deposit ratio to remain high, while others think it'll moderate soon, writes Shayan.Speaking of blockbuster mergers, let's talk about the one between Disney and Reliance. In February, Disney agreed to merge its India business with Reliance Industries at a cost of just over 3 billion dollars. This raised some eyebrows in the media and entertainment industry: reports stated that Disney had acquired Star earlier at around four to five times that number just five years ago, in a bid to consolidate its position in India. Mint's consumer bureau editor Gaurav Laghate analysed the transaction document to find the cause for this steep haircut. Gaurav reports that despite it being labelled as a merger, Reliance will essentially take control of the joint venture moving forward. The reports also revealed that Viacom18, Reliance's media arm, is sitting on a cash pile of over 1.9 billion dollars at the moment. That, combined with the lack of potential suitors, meant that Reliance had the upper hand throughout the negotiations. The final step? An approval from the Competition Commission of India, as the new entity will have more than a 40% market share in many media segments. Insiders told Gaurav that they are confident of an approval.Enterprise technology companies like to bundle their offerings. This ensures that they secure more revenue from their clients. A user may want just a single feature, but has to subscribe to the whole package. This process is called bundling – it's like eating at a buffet. However, you may soon be able to pick the service of your choice, a la carte. After a probe by the European Union, Microsoft unbundled MS Teams from its popular MS Office package. The EU ruled that Microsoft was abusing its market powers by forcing users to pay for the whole bundle that included MS Teams. India has powers to do this too: the India Competition Act of 2002 was supposed to act in the interest of the consumer. Mint's tech correspondent Shouvik Das explains that while such a move in India would provide more choices — especially for businesses, it will make cross-sharing of data very difficult. While privacy is generally a good thing, this could turn out to be a pain: imagine every single calendar invite needing approvals from multiple apps. If you're not a fan of MS Teams but use Outlook, you might be happy to read this Primer by Shouvik.Losing weight is usually a tough, long process. But drugs like Wegovy and Ozempic have changed that. a series of injections, and you shed kilos rapidly. But this magic drug hasn't reached the Indian shores yet: a patent is holding off Indian pharma companies from manufacturing liraglutide, which is the technical name of the drug. But Bloomberg reports that this patent only lasts till November. And India may have a willing maker already: Biocon, founded by Kiran Mazumdar-Shaw, has won approval from a regulator in the UK to sell the drug in India. Other companies are likely to bring their weight-loss drugs to the Indian market only in 2026. We'd love to hear your feedback on this podcast. Let us know by writing to us at feedback@livemint.com. You may send us feedback, tips or anything that you feel we should be covering from your vantage point in the world of business and finance. Show notes:Veritas Finance plans ₹2,000 crore IPODeposit crunch hits banks as key metric nears 20-year highDid Disney really take a big haircut merging its India assets with Reliance?Can breaking up Big Tech really help businesses?Generic weight loss drugs boosted by UK approval for Biocon
Thejna John is a happy woman. Last year, the relapse of an acute form of blood cancer despite a bone marrow transplant, had made her doctors give up all hope. In October, came a breakthrough. India approved the CAR T-Cell therapy, a revolutionary treatment for some forms of cancer. Thejna was one of the first cancer patients to undergo treatment in India. She is now cancer-free. The potential of CAR T-cell therapy is significant. And Pharma majors from Dr Reddy's to Biocon are pouring in money into their own CAR T-Cell projects. But it's early days. And questions remain: on efficacy, relapse, neurotoxicity and high costs. Join the conversation with host Anirban Chowdhury, Vikas Dandekar, ET's pharma expert, along with CAR T-Cell pioneer Dr. Hasmukh Jain, Associate Professor - Tata Memorial Centre, and Shirish Arya, Chief Business Officer - ImmunoACT as they discuss the future of this life-saving treatment on The Morning Brief podcast! Credits: TED If you like this episode from Anirban Chowdhury, check out his other interesting episodes on Fatigued & Flying: Why tired pilots are a wake-up call, Vizhinjam Port: Can Adani make India a global shipping hub?, Bhilai to Burj: The Rs. 5,000 Cr Bollywood Studded Mahadev Book Scam and more! You can follow Anirban Chowdhury on his social media: Twitter and Linkedin Catch the latest episode of ‘The Morning Brief' on ET Play, The Economic Times Online, Spotify, Apple Podcasts, Amazon Music and Google Podcasts. See omnystudio.com/listener for privacy information.
Show notes FDA Approves 10th Adalimumab Biosimilar, Simlandi Samsung Bioepis Announces New Biosimilar Partnership, Regulatory Updates Vizient Report Emphasizes Biosimilar Successes, Impact of Inflation on Drug Spend Eye on Pharma: VA Picks Hadlima; Biocon, Sandoz Partnership; A Stelara Settlement Abroad Eye on Pharma: Celltrion Biosimilars Win Tenders; Oral Ustekinumab Device Passes Phase 1 Trial Analyzing Safety of Switching From Originators to Biosimilars: A Meta-Analysis of 21 Trials Adalimumab Treatment May Impact Antibody Levels After COVID-19 Vaccination
Marketbuzz Podcast: The GIFT Nifty is indicating another flat start for the Indian markets. Watch out for stocks like Suven Pharma, Biocon, and Chalet Hotels.
Marketbuzz Podcast: The GIFT Nifty is indicating a flat to negative start for the Indian markets. Watch out for stocks like Whirlpool, Coal India and Biocon.
In this episode of Market Minutes, Harshita talks about the key factors to watch out for today before domestic equity market open. Nifty, Sensex may continue to fall on February 9 as after the hawkish tone of RBI, analysts expect the market to remain sideways and consolidate in the near term. Paytm, LIC, Torrent Power, Biocon, BHEL among some of stocks in focus. US indices end higher with S&P 500 nearing 5,000. Japan's Nikkei 224 at fresh 34-year high, while most Asian peers were either fully or partially closed for Lunar New Year holidays. Catch the global market set up, and also hear from Jigar Trivedi of Reliance Securities in the Voice of the Day segment. Market Minutes is a morning podcast that puts the spotlight on hot stocks, key data points, and developing trends
In this episode of Market Minutes, Harshita talks about the key factors to watch out for today before domestic equity market open. Q3 earnings and the RBI MPC meeting this week will guide Indian equities as investors eye interest rate cut commentary. Lupin, Biocon, Britannia and Nykaa are among some of stocks in in focus on February 7. US indices ended positively higher overnight higher as markets digested US firms' quarterly earnings and Fed commentary. Except for Japan, all Asian markets rose. Catch the global market setup, and also hear from V K Vijayakumar, Chief Investment Strategist at Geojit Financial Services in the Voice of the Day segment. Market Minutes is a morning podcast that puts the spotlight on hot stocks, key data points, and developing trends
Indian benchmark indices, Sensex and Nifty 50, are likely to scale new highs in the trading session of December 14, tracking global peers. The rally shall come after the US Federal Reserve flagged the end of its tightening cycle and struck a dovish tone on the interest rate outlook. India's GIFT Nifty was down 0.07% from its previous close at 21,227.50, as of 8:10 a.m., which implies the Nifty 50 will open higher than its last closing level of 20,926.35. In the overnight session, Wall Street equities surged with the Dow Jones Industrial Average gaining 1.4% to notch a record closing high. Asian stocks too followed US market shares and broadly rallied in morning trade on December 14. In the commodity space, oil prices rose in early Asian trade with Brent futures hovering around the $74 a barrel mark. The movements come after the Fed last night acknowledged that it is making "real progress" in easing inflation on the US, while maintaining a rate pause and adding that hikes were "not the base case anymore". Chair Jerome Powell said the Fed is aware of the risks of keeping rates higher for too long and lowering them too late, at a press conference after the policy decision, bolstering expectations of a rate cut in early 2024. Stocks to track in the domestic market: State Bank of India, NBCC, RBL Bank, Biocon, IndiGo and more Tune in to the Marketbuzz Podcast for more cues
Following a market holiday, Indian benchmark indices, Sensex and Nifty 50, are poised for a higher opening on November 15, propelled by a surge in global stocks. The surge is attributed to the softer-than-expected US inflation data, which has sparked optimism regarding a potential conclusion to the interest rate-hiking cycle in the world's largest economy. As of 7:59 a.m. IST today, India's GIFT Nifty was up 0.89%, reaching 19,731.50, approximately 300 points above the Nifty 50's closing figure on November 13. In the overnight Wall Street session, US equities climbed higher with the Nasdaq Composite index recording a 2.4% increase, marking its most robust performance in over six months. This upswing came after the US consumer price inflation (CPI) remained unchanged in October, a first in more than a year, following a 0.4% uptick in September. Simultaneously, early Asian trade witnessed a rise in oil prices attributed to escalating tensions in West Asia and a weakened dollar. Investors closely monitored inventory data following a two-week delay in reporting, with Brent futures maintaining levels around $82.5 per barrel. In the preceding session, Indian markets concluded with losses, although broader markets outperformed the benchmark indices. The overall market breadth, however, favoured declines. Goldman Sachs has upgraded its rating on Indian equities to the 'overweight' category. Additionally, MSCI released a list of stocks included in the global standard index. Key stocks to track include Biocon, IDFC First Bank, Rail Vikas Nigam, and Grasim Industries. Tune in to the Marketbuzz Podcast for more
Indian benchmark indices — Sensex and Nifty 50 — are likely to open the trading session of November 13 in green, a day after Samvat 2080 started on a strong note. On the day of Diwali Muhurat trading on November 12, Nifty 50 ended nearly 100 points higher at 19,523 and Sensex closed 350 points higher at 65,250. For the Nifty, 19,500-level was the level that the index managed to cross on the upside and that is now a key level to hold as it aims for 19,600. Meanwhile, the US markets ratings agency Moody's has downgraded the US credit rating outlook and thus, a certain amount of negative sentiment in US equity indices on November 10. However, for the last two consecutive trading weeks, all of the US indices ended with gains. In some further positive news flow for the domestic market, crude prices fell close to 5% in the week gone by with Brent futures now trading and hovering closer to the $80 a barrel mark. The earnings session has almost reached its final lap with a few more days left when listed companies will report their quarterly results. Grasim Industries and Manappuram Finance are due to report their earnings later in the day. Coal India, ONGC, SAIL, LIC, Biocon and Eicher Motors are among the other stocks in focus. Tune in to the Marketbuzz Podcast for more cues
In the recent market activity, we observed a range-bound performance with minor fluctuations. The Nifty Bank yesterday closed with a modest gain of around 25 points, while the midcap index rose by approximately 91 points. However, the overall market sentiment saw a dip of 143 points in the Sensex, and the Nifty also struggled to breach the levels around 19,004 to 19,500. In terms of institutional participation, net selling prevailed, with institutions selling over 1,700 crores and buying around 1,500 crores. This suggests that institutions remained net sellers in the market. One significant influence on the global markets was the hawkish comments made by Powell, which affected the US markets. The S&P witnessed a correction, breaking its longest winning streak since 2021, and the Asian markets followed suit. Additionally, oil prices hovered around $79 to $80 per barrel in response to these developments. Despite the Nifty indicating a lower start, macroeconomic factors may provide some support to cushion the market fall. In terms of corporate earnings, several companies, including Biocon, Coal India, ONGC, Tata Motors, Glenmark Pharmaceuticals, and Tata Chemicals, are scheduled to release their results, which will be closely watched by investors. Tune in to the Marketbuzz Podcast for more news and cues ahead of today's session
Indian benchmark indices — Sensex and Nifty 50 — are likely to open in green on November 9, after closing with minor gains in the previous session. In terms of big cues, oil has slipped further to three month lows below $80 per barrel for Brent crude as demand concerns have mounted. US markets closed marginally higher in the overnight session as stocks like Disney reacted positively to quarterly results. Asian peers also traded in the green in morning trade. Gift Nifty indicates a positive start for the domestic market. Amid earnings to track are Mahindra and Mahindra, Adani Ports, Apollo Hospital, Ashok Leyland, ABB India and more. Tata Power shares will also be in focus as several analysts have given it a 'sell' call amid collapse in Indo coal profits. Tune in to Marketbuzz Podcast for more cues
Indian benchmark indices — Sensex and Nifty 50 — are likely to open lower on September 21, Thursday, after the US Federal Reserve indicated it expected interest rates to remain higher for longer. The Federal Reserve on September 20 held interest rates steady but stiffened its hawkish stance with a further rate increase projected by the end of the year. The development in the US has left equity markets reeling under selling pressure. In the overnight session on Wall Street, the Dow Jones index ended 0.2 percent lower, S&P declined almost a percent while the tech-heavy Nasdaq index closed 1.5 percent lower. Asian stock markets took a hit as investors exited riskier assets to take refuge in the safe-haven greenback after the US central bank struck a hawkish tone. Meanwhile, Wednesday's trading session saw oil prices cool off from the recent peak. Oil prices have now hit a one-week low with futures hovering around the $90 a barrel mark. Back home in the Indian market, Nifty 50 ended below the 20,000 level on September 20. Heavyweight stock HDFC Bank was one of the top drags on the back of analysts cutting their estimates for the bank's earnings following an analyst meet. Stocks to Watch: Fino Payments, Cipla, Biocon, Adani Green Energy, Coal India Tune in to Marketbuzz Podcast for more news and cues ahead of today's session
A couple of days ago, Biocon announced that it had finally finished integrating Viatris' business with itself. And since this was probably Biocon's biggest acquisition till date, in today's episode for 9th September 2023, we thought it'd be a good time to see what this biopharmaceutical company has been up to. Watch our latest YouTube - https://www.youtube.com/watch?v=FO_NA4DKLVQ
In this episode of Market Minutes, Sucheta Anchaliya talks about all the important factors to watch today from TCS strategic investment to global market setup. Also catch Chetan Thacker, Senior Vice President - Portfolio Manager, ASK Investment Managers in Voice of the Day segment. Market Minutes is a morning podcast that puts the spotlight on hot stocks, keys data points and developing trends
The markets staged a smart recovery in the last hour of trade on Wednesday and the Nifty 50 managed to reclaim 19,600. The Nifty gained around 61-odd points, the Nifty Bank slipped, but the midcap index gained. Foreign institutional investors (FIIs) bought after nine consecutive sessions of selling, which is definitely a positive. FIIs net bought around Rs 644 crore in the cash market on Wednesday, while domestic institutional investors (DIIs) net sold close to around Rs 600-odd crore. The US markets were definitely weak, so we had the US markets correct. The CPI as well as the initial jobless claims would be two key factors that the Street would be watching out for closely. Asian stocks are lower ahead of the inflation data. Crude has hit the highest level that we have seen since January 27. So the Street will be waiting by for trends on brent crude. The GIFT Nifty is implying a weak start to today's trading session. It's definitely going to be the Reserve Bank of India (RBI) policy where rates are expected to be held steady, but do watch out for the commentary from the RBI governor. Today is also the weekly options expiry. And earnings from Hero MotoCorp, Biocon, Alchem Pharma, Pidilite, are expected today. Tune in to Marketbuzz Podcast for more cues ahead of today's session
Kiran Mazumdar Shaw, the brilliant founder of Biocon and a true trailblazer in the biotech industry. We talked for two hours straight, diving into her 40-year journey in biotech and her life beyond business. In my eyes, she is a testament to woman entrepreneurs in India; no one else comes close. Kiran is not just an inspiration to me professionally but also a dear friend and neighbour. Our bond has grown over the years, and I can't help but look up to her in so many ways. Her passion for transforming healthcare and giving back to society is incredible. It's a story that can't be missed, told in a more candid manner than ever before. Follow #NikhilKamath here: Twitter https://twitter.com/nikhilkamathcio/ Instagram https://www.instagram.com/nikhilkamathcio/ Facebook https://www.facebook.com/nikhilkamathcio/ Linkedin https://www.linkedin.com/in/nikhilkamathcio/ Koo https://www.kooapp.com/profile/Nikhilkamath Follow #KiranMazumdarShaw here: Twitter https://twitter.com/kiranshaw Instagram https://www.instagram.com/kiranmazumdar_shaw/?hl=en Linkedin https://www.linkedin.com/in/kmazumdarshaw/ Facebook https://www.facebook.com/KiranShaw1/#nikhilkamath #WTFiswithNikhilKamath #biocon #kiranmazumdarshaw #biotechnology #biopharmaceutics #pharma #medicine #women #dna #technology #enzymes #biology #brewing #beer #entrepreneur #entrepreneurship #startup 00:00 Intro 00:54 Did you know Kiran was a football fan? 02:20 Humble beginnings and the way of life 04:35 How Kiran became a brewmaster 7:24 Kiran's favourite beers as a pro taster 08:30 Kiran's take on friend Vijay Mallya 11:40 Lessons to learn from Vijay Mally's story 14:15 Kiran's challenges as a female brewmaster 16:40 Irish encounter: Serendipity in Kiran's entrepreneurial tale 20:20 The untold story: What held Kiran back from entrepreneurship 23:40 Enzyme technology - A deep dive 25:35 Ways to make enzymes 27:00 Greening effluents: A revolutionary treatment approach 30:14 Biocon: Garage days and a brave banker who bet on Kiran 34:29 Building a dream team: How Kiran attracted top talent 38:38 Empowering over 100 entrepreneurs 40:45 Golden entrepreneurial insight 42:40 What Kiran might have done differently 44:40 1998: IP, Unilever, global benchmarks - The turning point 48:10 How John charmed Kiran 50:50 AIG's incredible bet: How they got the best ROI! 53:12 Conquering global markets: How Biocon became the largest producer of statins 57:20 Pioneering anti-cancer and immunosuppressants 58:18 Transforming the insulin market: Biocon's groundbreaking role 1:00:40 Entrepreneurial pivots: Valuable insights for success 1:02:10 IPO: The launchpad to Kiran's billionaire status 1:05:20 How money defines Kiran 1:09:15 Nikhil & Kiran's personal journey: Kids & family 1:11:06 Demographic dynamics: India vs China fertility rates 1:12:00 The power of giving back: Nikhil's & Kiran's philanthropy; the Giving Pledge 1:14:43 The purpose behind this podcast 1:19:15 India's policies and pharma climate 1:22:10 Empowering India to lead, not follow! 1:23:15 Kiran's view on retirement at 70 1:24:42 Virtue signalling unmasked: A candid look at today's world 1:28:51 3 changes India needs 1:31:37 Empowering women in the workforce: Challenges and ESG perspectives 1:36:03 Women's roles across sectors at Biocon 1:38:05 IP ownership: The key to long-term profitability 1:40:45 How Biocon became the world's No. 1 biosimilar company 1:44:47 Unraveling Biocon: Is it a holding company? 1:45:43 Biotech startup guide: How to venture into the field 1:47:30 Bio-revolution: From cloning to designer babies 1:49:16 Biotech startups to watch out for 1:51:07 Hottest biotech sectors right now 1:53:31 An emotional tribute, Nikhil thanks Kiran 1:54:37 Kiran's secret to overcoming challenges 1:57:54 Pick the charity of your choice and be part of something incredible! 1:59:04 Outro
Shikhar Veer Singh and Nidhi Singh | Founders of Samosa Singh Samosa is a specialty snack of India and its available all over India and ofocurce in Indian retains the US and am sure other countries too.Shikhar began on a mission to disrupt the food business and started Samosa Singh. Shikhar has an extensive experience in food technology and has completed his master's degree from the premier Institute of Life Sciences, University of Hyderabad. Shikhar joined Biocon in 2009 as a scientist, but his talks at home kept returning to Samosas, or rather the business of Samosas. Slowly, theseed of a samosa business sprouted roots and shoots. The business concept was fine-tuned towards making a hygienic product and a distinctive one. Samosa Singh was founded in 2016 withthe goal of reinventing the king of Indian snacks, the samosa. The company has expanded at an exponential rate under Shikhar's leadership. Samosa Singh now functions from a big, largely automated facility with proprietary automation that is capable of handling good order volumes. Aside from hisactive participation in the business, he enjoys traveling. He also works out rigorously to stay fit because he is a great believer that being healthy equals being wealthy.Nidhi Singh is the Co-Founder of Samosa Singh. Nidhi was heading the Business developmentvertical for a US-based healthcare company, BioXcel Corporation. She worked a decade before quittingher satisfying job to start Samosa Singh. She decided to invest in a hygienic startup after garnering over 10 years of experience in marketing. She aspires to offer nostalgic and Indian delicacies both online andoffline. She believes that the goal is to recreate and dominate the Indian snack category.
In this episode of Market Minutes, Asha Menon talks about global markets' cautious waiting for talks in US to reach a resolution and why oil prices are inching up while gold is slipping. Also, Sanjay Manyal, Senior Research Analyst at ICICI Securities, shares why he believes the ITC rally has a longer run and which are the verticals he is optimistic about. Market Minutes is a morning podcast that puts the spotlight on hot stocks, keys data points and developing trends (with inputs from Shivam Shukla).
Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women's Hospital, and Co-Director of the Center for Infection and Immunity, at the Brigham Research Institutes, Boston. He is also an associate member of the Broad Institute, and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is the founding Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women's Hospital. His major research interests include autoimmune diseases—particularly the role of co-stimulation—the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, as well as cell surface molecules and regulatory factors that regulate the induction of T cell tolerance and dysfunction. His laboratory bred several transgenic mice that serve as animal models for human multiple sclerosis. The Kuchroo laboratory was also the first to describe the TIM family of genes, and identified Tim-3 as an inhibitory receptor expressed on T cells, which is now being exploited for cancer immunotherapy. He was first to describe the development of highly pathogenic Th17 cells, which have been shown to induce multiple different autoimmune diseases in humans. Kuchroo is the lead author on a paper describing the development of Th17, which is one of the most cited papers in the field of Immunology.Kuchroo came to the United States in 1985, as a Fogarty International Fellow at The National Institutes of Health, Bethesda, MD for one year, before joining the department of pathology at Harvard Medical School, as a research fellow. Later, he joined the Center for Neurologic Diseases at Brigham and Women's Hospital as a junior faculty member in 1992.He obtained his degree in Veterinary Medicine from the College of Veterinary Medicine, Hisar, India. Subsequently, he specialized in pathology at the University of Queensland, Brisbane Australia, where he obtained a Ph.D. in 1985. He received the Fred Z. Eager Research Prize and medal for his Ph.D. research work at the University of Queensland. Based on his contributions, he was awarded the Javits Neuroscience Award by the National Institutes of Health in 2002 and the Ranbaxy prize in Medical Research from the Ranbaxy Science Foundation in 2011. He was named Distinguished Eberly Lecturer in 2014, and obtained a Nobel Laureate Peter Doherty Lecture/Prize in 2014.Kuchroo has 25 patents and has founded 5 different biotech companies including CoStim Pharmaceuticals and Tempero Pharmaceuticals. He also serves on the scientific advisory boards and works in advisory capacity to a number of internationally recognized pharmaceutical companies including: Biocon, Syngene, Pfizer, Novartis and Glaxo-Smith-Klein (GSK).Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)
On this episode of the Grow Everything Biotech Podcast, hosts Karl and Erum were joined by Charles Dimmler of Checkerspot to discuss sustainable materials created using microbes. They talked about Checkerspot's mission to create sustainable products with superior performance, the potential of exploring microbes for scientific discoveries, and Biden's Bioeconomy Executive Order. They also talked about different sustainable materials such as urethane-based products, disintermediation, material sourcing, and the challenges posed by the climate crisis. This episode covered a wide range of critical ideas surrounding biotech, sustainability, and innovation. Grow Everything brings to life the bioeconomy when hosts Karl Schmieder and Erum Azeez Khan share stories from the field and interview leaders and influencers in the space. Life is a powerful force and it can be engineered. What are we creating? Learn more at www.messaginglab.com/groweverything Topics Covered: 0:00:00 Cherry Blossoms Blooming In Brooklyn Botanical Garden 00:04:03 Biden's Biocon Executive Order: Progress And Opportunities For Education On Growing Everything 00:05:07 Unpacking The Biden Biocon Blueprint And The Goal Of Growing Everything 00:08:56 Introduction To Checkerspot And Its Founding Story 00:11:34 Commercializing Microalgae Fermentation For Empowerment Of Third Parties 00:16:57 New Developments In Urethane-based Record Technology Showcased At South By Southwest 00:22:00 Biocon's Strategic Focus On Making Bio Manufacturing More Accessible And Relevant 00:25:24 Checkerspot's Unique Model For Sustainable Product Development And Testing 00:30:22 Disintermediation And The Importance Of Provenance In Consumer Brands' Material Sourcing 00:32:21 Pollinator Kit Enables Product Designers To Experiment With Cast Urethane 00:36:49 Non-vinyl Record And Other Applications Of Empowering Material 00:40:57 Company Headquarters In Alameda, CA 00:43:47 Checkerspot: Combining Performance And Sustainability In Product Design 00:51:27 Interview With Charles About A 10-20 Year Time Frame For A Project. 00:57:11 Podcast Gains Impressive Traction With Nearly 4000 Plays Episode Links: Charles Dimmler on Twitter Charles Dimmler on LinkedIn Checkerspot Website Unstable BioHackers Call or Text the Grow Everything Hotline: +1 804-505-5553 Have a question or comment? Message us here: Instagram / TikTok / Twitter / LinkedIn / Youtube / GrowEverything website Email: groweverything@messaginglab.com Support here: Patreon Music by: Nihilore Production by: Amplafy Media --- Send in a voice message: https://podcasters.spotify.com/pod/show/messaginglab/message
Co-founder and former chief technology officer of cloud company Confluent, Neha Narkhede's journey from Pune to the Silicon Valley, and from a software engineer to Forbes' list was quite phenomenal. And why she is in the news now. With a net worth estimated at 13,380 crore rupees, Narkhede has been ranked eighth in the Leading Wealthy Women 2021 list compiled by Hurun. She can now count herself among the likes of HCL Technologies chairperson Roshni Nadar Malhotra, who topped the Hurun list for the second year in a row, Falguni Nayar, the promoter of FSN E-Commerce, and Kiran Mazumdar-Shaw of Biocon. Narkhede was raised in Pune, Maharashtra. By way of her own account to the press, we know the source of her inspiration in her formative years. So it is no surprise then that she decided to break into the male-dominated tech sector. Narkhede first went to the University of Pune and received her Bachelor of Science in Engineering from SCTR'S Pune Institute of Computer Technology college. In 2006, she left India to get her master's in computer science from Georgia Tech. After graduating in 2007, she started a job at Oracle. After Oracle, Narkhede worked as a software engineer at LinkedIn, where she was involved in the development of Apache Kafka, an open-source messaging system designed to handle the networking site's large data input. This would prove to be a pivotal point in her coming entrepreneurial life. It was in 2014 that she and two LinkedIn colleagues left the company to found Confluent. Now, let us know about the company. Headquartered in Mountain View, in California in the United States, Confluent offers organisations an Apache Kafka-based streaming platform that enables them to easily access data in the form of real-time streams.
Kiran Mazumdar-Shaw trained as a master brewer, but in late-1970s India she was rejected by the beer industry – it wasn't seen as a job for a woman. Undeterred, she put her scientific mind and entrepreneurial prowess to setting up what would become one of India's largest pharmaceutical companies, Biocon. She tells Rahul Tandon about her humble beginnings in business, overcoming challenges and inspiring other female entrepreneurs. Presenter: Rahul Tandon Producers: Rahul Tandon, Sam Clack, Rory Claydon Image: Kiran Mazumdar-Shaw; Credit: Biocon
First, Indian Express's Udit Misra talks to host Utsa Sarmin about central banks raising interest rates to tackle rising prices of food and fuel.Second, Deeptiman Tiwari joins us to talk about the bribery case in which the Central Bureau of Investigation arrested the joint drug controller S Eswara Reddy and executives of Bionic Biologics. And in the end, Indian Express's Pranavl Mukul talks about the bird strikes that grounded two aircraft on Sunday, and why such incidents can be dangerous.
Equity markets have been volatile of late, given the turmoil in global markets. The ongoing Ukraine crisis, high commodity prices and a likely onset of higher interest rate regime have kept bulls on the sidelines. Back home, disappointment on the earnings front have also plagued select stocks, thus adding to the woes. So far in April the NSE Nifty has swung in a wide range of nearly 1,300 points. From a high of 18,115, the index dropped to a low of 16,825, before recouping some of its lost ground. Still, the index is down over 3 per cent on a month-to-date basis. Among the Nifty 50 stocks Mahindra & Mahindra, Adani Ports, NTPC, Eicher Motors and Shree Cement have been the major gainers so far, while Hindalco, Tech Mahindra, Infosys, Wipro and Bajaj Finserv are the major losers. According to Kunal Shah, Senior Technical & Derivative Analyst, LKP Securities, April F&O series was one of the most volatile series in recent times. It saw selling pressure at higher end on Nifty and Nifty Bank, while Lower Top, Lower Bottom formation was seen on charts. Now, the stage is set for a tug-of-war between the bulls and bears on the expiry day. As per the options data, the highest open interest is seen in 17,500 Call and 17,000 Put. Higher open interest in Call indicates resistance and vice versa in case of the Puts. On Wednesday, the 17,000 and 17,100 Calls saw significant build-up in open interest. And, at the same time, the 17,000 Put saw heavy addition. This trend suggests investors should brace themselves for a fierce tug-of-war in the range of 16,950-17,150. A significant breakout on the lower side of the range can trigger a sharp sell-off. On the other hand, a sustained trade above 17,150 can trigger a short-covering rally. According to Manojh Vayalar of Religare Broking with FIIs focussed more on index options, volatility could be high today. A close above 17,250 on the Nifty and above 36,500 on the Bank Nifty can lead to over 400 points and 1,200 points rally on both the indices during the first week of May. Meanwhile, apart from the F&O expiry induced volatility, markets may eye global cues for further trajectory. Moreover, stock specific action amid Q4 results season will remain high. Shares of Ambuja Cements, Axis Bank, Bajaj Finserv, Biocon and Vedanta are likely to be in focus as the companies are scheduled to announce their Q4 earnings. The primary market, too, will see some action with the ongoing IPOs of Campus Activewear and Rainbow Children's Medicare. Further, the mega 21,000 crore rupees LIC IPO shall open for subscription on May 4, next week. Watch video
Join us as we talk to Aniket Deb, the Co-Founder of Bizongo about their story. About Aniket Deb: He is the Co-Founder and COO at Bizongo, a full stack supply chain enablement platform for customised goods. He graduated from IIT Bombay in 2013 and founded Bizongo in 2015. While working for Housing.com, Opera Solutions, EY and Biocon prior to establishing his own company, he gained extensive experience. About Bizongo: Bizongo is a full stack supply chain enablement platform for customised goods. The company today focuses upon packaging, textiles, apparels & other contract manufacturing goods as its product portfolio and has a network of over 1500 curated manufacturers across these categories. Through its proprietary digital platforms, such as Procure Live, Partner Hub, and Artwork Flow it is offering Digital Vendor Management, Supply Chain Automation & Supply Chain Financing as key services to its enterprise customers. Today, it services more than 120 enterprise customers in fashion & lifestyle, pharmaceuticals, consumer discretionary, consumer staples, home & personal care and e-commerce.
Barring just one instance, she never endorsed a brand in her lifetime. But her death united all the brand leaders in grief. Her volley of work not just gave them momentary escape from the everyday hassle, but also offered lessons in creation and brand building. Leading industrialist Anand Mahindra tweeted: “What can you say when you no longer have your voice...? Om Shanti.” While Adani Group chairman Gautam Adani said, “The voice, the charm, the melodies will live on for generations to come.” Kiran Mazumdar-Shaw, the executive chairperson of biotechnology major Biocon, said, “Lata Mangeshkar will eternally cast her large shadow over us n remind us of he us of her eternal legend.” Her voice will indeed eternally cast a large shadow over this subcontinent's music. Despite her massive celebrity status, which stretched across decades and beyond India's borders, Lata Mangeshkar, unlike most other celebrities, shied away from endorsing day-to-day brands. There is no consolidated figure on what her songs earned. However, there a mountain of evidence on how much her voice drove the Rs 1,800-crore Indian music business, which is now dominated by streaming. More than 192 million Indians tune in to some streaming app or the other every month. India's oldest music label, Saregama is home to 130,000-plus songs. Every time any of these is played on streaming apps - YouTube, Spotify, Gaana-- used by short video apps (Moj, Josh) or on TV (ads, shows), Saregama gets paid. In the financial year 2020-21, the company earned Rs 284-crore, or three-fourths of its revenue, from such licensing of songs by Lata Mangeshkar, Mohammed Rafi, Kishore Kumar et al. Songs from Saregama's catalogue were streamed 85 billion times in the last financial year. “Lata Mangeshkar was the tallest singer we had,” managing director of Saregama, Vikram Mehra said. Mangeshkar's songs were streamed 6.7 billion times on her YouTube channel in the last 12 months. This figure can shock even the star influencers. The top songs on it are “Didi Tera Dewar Deewana” (Hum Aapke Hain Kaun, 1994), “Yeh Galiyan Yeh Chaubara” (“Prem Rog”, 1982), and “Ho Gaya Hai Tujhko To Pyaar Sajna” (Dilwale Dulhania Le Jaayenge, 1995). She has remained on the YouTube list of top 10 Indian artists along with many of her younger colleagues such as Alka Yagnik or Arijit Singh. And she has been at number 11 on the top global artists chart, for over 294 weeks now. Mangeshkar's songs or videos are streamed millions of times from a variety of other platforms -- Shemaroo, Saregama, Spotify, Gaana, to name a few. In 2013, Mangeshkar endorsed a brand, breaking her lifetime resolve. She appeared in an ad for cough syrup Glycodin. The others who come in from the cold included Bismillah Khan and Bhimsen Joshi. When asked why Glycodin, she replied, I can afford anything except a sore throat!” Watch video
As benchmark indices head lower due to rising global headwinds, stock-specific opportunity amid Q3 results is helping investors trim losses. So far, the December quarter results have, largely, been positive for the Street with majority of the companies, including Infosys, TCS, HDFC Bank, Bajaj Finance and Metro Brands posting better-than-expected earnings growth. And now, all eyes will be on the earnings report card of index major Reliance Industries, which is scheduled to report its results, tomorrow. Global brokerage Morgan Stanley expects the two Rs – Refining and Retail – to drive the earnings in Q3 with demand and margin surprises likely in both these segments. For the quarter, the brokerage projects a 9% quarter-on-quarter earnings growth, driven mostly by improvement in gasoline and diesel margins. This will be further supported by retail demand in jewellery, electronics and grocery, for which RIL has already reported positive surprises. Overall, the brokerage expects consolidated EBITDA to rise by 8.5% QoQ and 28.5% YoY at Rs 27,722.6 crore. This would be driven by oil to chemicals EBITDA growth of 10% QoQ; telecom growth of 2% QoQ, and retail growth of 35% YoY. Back home, analysts at Emkay Global peg EBITDA growth at 37% YoY and 14% QoQ, while net profit is seen at Rs 16,138 crore, up 23% YoY and 18% QoQ. On a standalone basis, analysts expect RIL's EBITDA to increase anywhere between 12-15%. Standalone net profit, on the other hand, is seen at Rs 9,906.6 crore, up 13% YoY and over 7% QoQ. The stock of Mukesh Ambani-led company has advanced over 6% year-to-date on the bourses, and analysts expect it to rise another 17%, up to Rs 2,955 apiece, over the next one year. This will be triggered by a combination of higher chemical margins, details on the new energy vertical, and new partnerships in key segments. As regards Thursday's session, global headwinds and weekly F&O expiry will likely keep the indices choppy through the day. The frontline Sensex index has tumbled over 1,200 points in 2 days and stands at 60,099 level. The Nifty50, meanwhile, has broken below the 18,000-mark and is at 17,938. On the earnings front, over 40 companies, including Asian Paints, Bajaj Finserv, Biocon and HUL are scheduled to report their results today. Among the lot, Hindustan Unilever is likely to clock year-on-year revenue growth of 9-12 per cent in on account of price hikes taken in recent quarters. Analysts, however, expect its volume growth to be flat. Moreover, analysts expect nearly 200 basis points YoY fall in the company's gross margins due to high commodity inflation. Stock-specific action, initial public offer of AGS Transact Technologies, and news flow around the Omicron variant of Covid-19 will be the other key triggers. Watch video
Top headlines · Sensex sheds 656 points, Nifty ends below 18K amid weak global cues · Bajaj Finance hits new high on Q3 results; falls on profit-booking later · Paytm hits new low; declines 26% in three weeks · Sterlite Tech tanks 7% on disappointing Q3 numbers · AGS Transact Technologies IPO subscribed 85% on day 1 The benchmark indices on Wednesday ended with deep cuts as they extended losses for a second day amid weak global cues and rising bond yields. The 10-year US Treasury yield hit 1.9% today, its highest level since December 2019. Meanwhile, the UK saw its inflation rate soaring to a 30-year high of 5.4% in December. Given this, the frontline BSE Sensex plunged 656 points, or 1.08%, to close at 60,099 after hitting an intra-day low of 59,949. The NSE Nifty50 ended below the 18,000 mark, at 17,943, down 170 points or 0.9 per cent. Among the laggards, Infosys, ICICI Bank, HDFC and TCS together accounted for almost 60% of the loss for the Sensex. Asian Paints, Hindustan Unilever, Bajaj Finance, Kotak Bank, and Nestle were the other major draggers. The broader indices, however, outperformed the benchmarks, with the BSE MidCap index ending 0.34% lower and the BSE SmallCap rising marginally by 0.03%. Sectorally, barring auto, metals and energy, all other Nifty indices closed in the red, led by IT which was 2% lower. FMCG and financials were the other major losers, down 1% each. The Nifty PSB index, on the other hand, was the top gainer, up 2% after reports said the government had cut FY22 recapitalisation amount for public banks to Rs 15,000 crore due to lower demand. That apart, among stocks, the shares of Bajaj Finance hit a record high of Rs 8,043 on the BSE after the NBFC reported a strong 85% year-on-year jump in consolidated profit after tax in Q3, beating Street estimates. However, the stock later fell on profit booking and closed 2.3% lower. On the flip side, the stock of Paytm parent One97 Communications, hit a new low, which was less than 10 per cent away from touching Macquarie's downgraded target price of Rs 900 apiece. The stock has slipped 26% in the past three weeks and at present it is 54% below its issue price. Further, Sterlite Technologies also tanked 7.5% after a disappointing set of December quarter numbers. The company posted net loss of Rs 137.1 crore, as against a profit of Rs 86.6 crore a year earlier. Its revenues stood at Rs 1,356 crore, up 3.1% from last year. In the primary market, the IPO of AGS Transact Technologies was subscribed 85% as of 4:00 pm on the first day of its subscription. The retail investor and the non-institutional investors portions were subscribed 1.3 times and 1 time, respectively, whereas the qualified Institutional buyer portion was not subscribed at all. Lastly, companies like Asian Paints, Hindustan Unilever, Bajaj Finserv and Biocon will announce their Q3 results on Thursday. These will all be keenly watched.
In a significant development this year, the United States Food and Drug Administration granted interchangeable status to two biosimilar drugs— Biocon's diabetes drug insulin glargine branded as Semglee and Boehringer Ingelheim's biosimilar Cyltezo. In this edition of The Medicine Box Podcast season 5, CNBC-TV18's Ekta Batra talks to Kiran Mazumdar-Shaw, the chairperson of Biocon, about Semglee, the first interchangeable biosimilar insulin product to have received approval from the US drug regulator for the treatment of diabetes. Interchangeability essentially means a pharmacist in the US can give a person the drug approved with an interchangeable status other than reference biologic on prescription. The development possibly paves the way for more life-saving drugs seeing greater accessibility and reducing price. Shaw also talks about Cyltezo, which is the biosimilar version of one of the world's largest selling biologic drugs Humira, used for arthritis and other conditions. Tune in to The Medicine Box Podcast to find out more about interchangeable biosimilars, their competition, prices, and more.
Originally Published as The Niche PodcastThis week, look closer – with drops, controlled gene therapy, acquisitions in antibodies, new antifungals, new biosimilars, and several IPOsFind out more athttps://thenichepod.comStory Referenceshttps://tinyurl.com/Niche-061-1https://tinyurl.com/Niche-061-2https://tinyurl.com/Niche-061-3https://tinyurl.com/Niche-061-4https://tinyurl.com/Niche-061-5https://tinyurl.com/Niche-061-6https://tinyurl.com/Niche-061-7https://tinyurl.com/Niche-061-8Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodsonAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.
Mr Kulbhushan Chattoo is an MBA graduate with specialization in Marketing and a focus on Finance. He is currently responsible for Portfolio and Alliance Management at Novartis, one of the largest global pharmaceutical companies. He has spent over a decade in the healthcare/pharma industry including previous stints with Cipla and Biocon. His insightful and decisive nature helped him sail through the most challenging setback he faced during his crucial year of engineering..........his success story will definitely hold a torch of hope for others
© 2020-2025 Ivy Podcast Discovery LLC
